GNMSF - IDNA: The Cutting Edge Of Medical Science Is A Risky Investment
2025-04-20 11:28:23 ET
Summary
- The iShares Genomics Immunology and Healthcare ETF is invested in 49 companies involved in genomics, immunology and bioengineering.
- Compared with the biotechnology benchmark IBB, IDNA has value characteristics, but has greatly underperformed, losing over 20% since its inception.
- Among genomics-focused ETFs, PBE offers a relatively safer choice with better performance and lower volatility.
IDNA strategy
iShares Genomics Immunology and Healthcare ETF ( IDNA ) was launched on 6/11/2019 and tracks the NYSE® FactSet® Global Genomics and Immuno Biopharma Index. IDNA has a portfolio of 49 stocks (plus cash in several currencies and derivatives), a 30-day SEC yield of 0.85% and an expense ratio of 0.47%. Distributions are paid semi-annually. As described in the prospectus by iShares ,...
IDNA: The Cutting Edge Of Medical Science Is A Risky Investment